What is Ogivri™ (trastuzumab-dkst)?
Ogivri is a targeted treatment used to treat certain people with metastatic breast cancer that is positive for the human epidermal growth factor receptor 2 (HER2+). It is used for HER2+ metastatic breast cancer:1,2
- In combination with paclitaxel as a first-line treatment
- Alone in people who have previously been treated with at least one chemotherapy course for metastatic breast cancer
Metastatic breast cancer is cancer that has spread to other parts of the body, such as the bones or liver. Breast cancer tumors are defined as HER2+ or HER2- cancers. HER2 refers to a specific protein that appears on the surface of cancer cells and can lead to faster growth and spread of the cancer. When cancer cells produce too many HER2 molecules, they are called HER2+ tumors.1,2
Ogivri is also used as adjuvant therapy for certain forms of HER2+ early breast cancer. Adjuvant therapy attempts to keep cancer from coming back after initial treatment, like surgery.1,2
Ogivri is a biosimilar to Herceptin® (trastuzumab). Approved biosimilar drugs have no clinically meaningful differences from their approved reference product.1,2
What is the active ingredient in Ogivri?
The active ingredient in Ogivri is trastuzumab-dkst.1
How does Ogivri work?
Ogivri is a monoclonal antibody. Antibodies are a normal part of our immune system that act against antigens. These include bacteria, viruses, and other foreign organisms that threaten our health. Monoclonal antibodies used in cancer treatment are created in a laboratory to attach to specific antigens on the surface of cancer cells.1
Breast cancers that are classified as HER2+ have too many HER2 receptors. This can cause the cancer to grow and spread quickly. Ogivri targets these receptors and can slow or block the growth and spread of HER2+ breast cancers.1
What are the possible side effects of Ogivri?
The most common side effects of Ogivri in breast cancer treatment include:1
- Trouble sleeping
- Heart problems
Ogivri has a boxed warning, the strictest warning from the U.S. Food and Drug Administration (FDA). This is because it may cause severe side effects, including:
- Heart problems, including congestive heart failure
- Lung damage
- Infusion-related reactions
- Birth defects and death in unborn babies
These are not all the possible side effects of Ogivri. Talk to your doctor about what to expect or if you experience any changes that concern you during treatment with Ogivri.
Things to know about Ogivri
Your doctor will monitor your heart function before and during treatment with Ogivri.1
Ogivri can harm an unborn baby. If you can become pregnant, you should use birth control during treatment and for some time after the last dose of Ogivri. Talk to your doctor about your options for birth control while while taking Ogivri. Additionally, if you are breastfeeding or plan to breastfeed, talk with your doctor about this consideration to make sure you have a plan that is safe before starting treatment.1
Before beginning treatment for breast cancer, tell your doctor about all your health conditions and any other drugs, vitamins, or supplements you are taking. This includes over-the-counter drugs.
For more information, read the full prescribing information of Ogivri.